Pfizer touts inhaled insulin

Pfizer is touting new clinical trial data that shows its inhaled version of insulin -- Exubera -- works just as well as the injectable kind and was well tolerated by patients over a period of two years. The results were released at a meeting of the American Diabetes Association. Pfizer believes that an inhaled version of insulin will offer higher compliance rates. Pfizer is developing the experimental drug with Sanofi-Aventis and Nektar Therapeutics. The FDA is expected to take action on their drug application by October.

- read this article from for more

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

While the biotech IPO market booms, it can look like going public is easy. But the right strategy, syndicate and aftermarket are still important.

Gene therapy pioneer Jim Wilson and the University of Pennsylvania are teaming up with Regeneron to help deliver its COVID antibody intransally.

Forty percent of PK deficiency patients on mitapivat had hemoglobalin responses, compared to 0% in the placebo group.